Each row is a drug, each column a cancer subtype. Cells show the strongest known association for that drug in that cancer: approved clinical trial or blank. The repositionable flag means the drug appears as a synthetic-lethal repositioning candidate in cansar; it’s gene-level, not cancer-level.
| Drug | Target | Relationship | GBM | LUAD | SCLC | LUSC | OAC | OSCC | PDAC | Reposition | #cancers |
|---|---|---|---|---|---|---|---|---|---|---|---|
| adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib | ALK | Direct | 3 | ||||||||
| crizotinib | ALK | Direct | yes | 3 | |||||||
| alectinib, brigatinib, lorlatinib 100 mg, osimertinib, sotorasib, dabrafenib, trametinib, selpercatinib, pembrolizumab, cemiplimab, nivolumab, carboplatin, pemetrexed, paclitaxel | ALK | Direct | 2 | ||||||||
| alectinib, stereotactic radiosurgery | ALK | Direct | 2 | ||||||||
| entrectinib, entrectinib, alectinib, atezolizumab, ipatasertib, trastuzumab emtansine, idasanutlin, inavolisib, belvarafenib, pralsetinib, gdc-6036, camonsertib | ALK | Direct | 2 | ||||||||
| apg101, alectinib, idasanutlin, atezolizumab, vismodegib, temsirolimus, palbociclib | ALK | Direct | 1 | ||||||||
| biopsy, biospecimen collection, crizotinib, radiologic examination | ALK | Direct | 1 | ||||||||
| ceritinib, cisplatin, gemcitabine hydrochloride, laboratory biomarker analysis, paclitaxel albumin-stabilized nanoparticle formulation, pharmacological study | ALK | Direct | 1 | ||||||||
| lorlatinib, lorlatinib with chemotherapy1, lorlatinib with chemotherapy 2, lorlatinib post radiation | ALK | Direct | 1 | ||||||||
| alectinib | ALK | Direct | yes | 0 | |||||||
| alectinib hydrochloride | ALK | Direct | yes | 0 | |||||||
| brigatinib | ALK | Direct | yes | 0 | |||||||
| ceritinib | ALK | Direct | yes | 0 | |||||||
| entrectinib | ALK | Direct | yes | 0 | |||||||
| lorlatinib | ALK | Direct | yes | 0 | |||||||
| adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib | BTK | SSL via BTK | 3 | ||||||||
| adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib | SMO | SSL via SMO | 3 | ||||||||
| alvocidib, paclitaxel | CDK9 | SSL via CDK9 | 2 | ||||||||
| bevacizumab, dasatinib, fluorouracil, leucovorin, leucovorin calcium, oxaliplatin, quality-of-life assessment | BTK | SSL via BTK | 2 | ||||||||
| ibrutinib | BTK | SSL via BTK | yes | 2 | |||||||
| motexafin gadolinium, radiation therapy | RRM2 | SSL via RRM2 | 2 | ||||||||
| pembrolizumab, sonidegib | SMO | SSL via SMO | 2 | ||||||||
| 3-dimensional conformal radiation therapy, motexafin gadolinium, temozolomide | RRM2 | SSL via RRM2 | 1 | ||||||||
| afatinib, dasatinib, palbociclib, everolimus, olaparib | BTK | SSL via BTK | 1 | ||||||||
| alvocidib, docetaxel | CDK9 | SSL via CDK9 | 1 | ||||||||
| alvocidib, gemcitabine hydrochloride, 3-dimensional conformal radiation therapy, laboratory biomarker analysis | CDK9 | SSL via CDK9 | 1 | ||||||||
| apg101, alectinib, idasanutlin, atezolizumab, vismodegib, temsirolimus, palbociclib | SMO | SSL via SMO | 1 | ||||||||
| ascorbic acid, paclitaxel protein-bound, cisplatin, gemcitabine | DBH | SSL via DBH | 1 | ||||||||
| atezolizumab, tivozanib | PTK6 | SSL via PTK6 | 1 | ||||||||
| bevacizumab, dasatinib, placebo | BTK | SSL via BTK | 1 | ||||||||
| biopsy, biospecimen collection, echocardiography, radionuclide imaging, vismodegib | SMO | SSL via SMO | 1 | ||||||||
| chemotherapy, cladribine, radiation therapy | RRM2 | SSL via RRM2 | 1 | ||||||||
| chemotherapy, disulfiram, gemcitabine hydrochloride, laboratory biomarker analysis | DBH | SSL via DBH | 1 | ||||||||
| conventional surgery, 3-dimensional conformal radiation therapy, stereotactic radiosurgery, motexafin gadolinium, magnetic resonance imaging, spectroscopy | RRM2 | SSL via RRM2 | 1 | ||||||||
| dasatinib, erlotinib hydrochloride, gemcitabine hydrochloride | BTK | SSL via BTK | 1 | ||||||||
| dasatinib, gemcitabine hydrochloride, laboratory biomarker analysis, mutation analysis, nucleic acid sequencing, immunohistochemistry staining method | BTK | SSL via BTK | 1 | ||||||||
| dasatinib, laboratory biomarker analysis, physiologic testing | BTK | SSL via BTK | 1 | ||||||||
| dasatinib, mfolfox6 | BTK | SSL via BTK | 1 | ||||||||
| dasatinib, pharmacological study | BTK | SSL via BTK | 1 | ||||||||
| dasatinib, temozolomide, placebo, radiation therapy | BTK | SSL via BTK | 1 | ||||||||
| diagnostic laboratory biomarker analysis, erlotinib hydrochloride, gemcitabine hydrochloride, vismodegib | SMO | SSL via SMO | 1 | ||||||||
| disulfiram, copper gluconate, surgery, radiation, temozolomide | DBH | SSL via DBH | 1 | ||||||||
| disulfiram, copper, alkylating agents | DBH | SSL via DBH | 1 | ||||||||
| gemcitabine hydrochloride, hydrocortisone/placebo, vismodegib | SMO | SSL via SMO | 1 | ||||||||
| gemcitabine, ribociclib, sonidegib, trametinib, filgrastim | SMO | SSL via SMO | 1 | ||||||||
| ibrutinib, durvalumab | BTK | SSL via BTK | 1 | ||||||||
| ibrutinib, fludarabine | BTK | SSL via BTK | 1 | ||||||||
| ibrutinib, gemcitabine, nab-paclitaxel | BTK | SSL via BTK | 1 | ||||||||
| ibrutinib, indoximod, cyclophosphamide, etoposide | BTK | SSL via BTK | 1 | ||||||||
| ibrutinib, paclitaxel, gemcitabine | BTK | SSL via BTK | 1 | ||||||||
| ibrutinib, radiation, temozolomide (tmz) | BTK | SSL via BTK | 1 | ||||||||
| imexon, gemcitabine | RRM2 | SSL via RRM2 | 1 | ||||||||
| lutetium lu 177 dotatate, capecitabine, temozolomide, quality-of-life assessment, questionnaire administration | SSTR5 | SSL via SSTR5 | 1 | ||||||||
| motexafin gadolinium | RRM2 | SSL via RRM2 | 1 | ||||||||
| motexafin gadolinium, magnetic resonance imaging, surgical procedure | RRM2 | SSL via RRM2 | 1 | ||||||||
| oxaliplatin, irinotecan hydrochloride, leucovorin calcium, fluorouracil, ascorbic acid | DBH | SSL via DBH | 1 | ||||||||
| ryz101, everolimus, sunitinib, octreotide, lanreotide | SSTR5 | SSL via SSTR5 | 1 | ||||||||
| sirolimus, vandetanib | PTK6 | SSL via PTK6 | 1 | ||||||||
| sorafenib, radiofrequency ablation (rfa) or surgery, everolimus, lanreotide | SSTR5 | SSL via SSTR5 | 1 | ||||||||
| temozolomide, aprepitant, minocycline, disulfiram, celecoxib, sertraline, captopril, itraconazole, ritonavir, auranofin | DBH | SSL via DBH | 1 | ||||||||
| temozolomide, disulfiram, copper gluconate | DBH | SSL via DBH | 1 | ||||||||
| temozolomide, radiation therapy, ascorbic acid | DBH | SSL via DBH | 1 | ||||||||
| tivozanib | PTK6 | SSL via PTK6 | 1 | ||||||||
| trilaciclib | CDK9 | SSL via CDK9 | 1 | ||||||||
| vandetanib | PTK6 | SSL via PTK6 | yes | 1 | |||||||
| vandetanib, 5 fluorouracil (fu), carboplatin, paclitaxel, external beam radiation therapy (rt) | PTK6 | SSL via PTK6 | 1 | ||||||||
| vandetanib, adjuvant therapy | PTK6 | SSL via PTK6 | 1 | ||||||||
| vismodegib, sirolimus, positron emission tomography, computed tomography, pharmacological study, laboratory biomarker analysis, fludeoxyglucose f 18 | SMO | SSL via SMO | 1 | ||||||||
| vismodegib, therapeutic conventional surgery, laboratory biomarker analysis, pharmacological study | SMO | SSL via SMO | 1 | ||||||||
| acalabrutinib | BTK | SSL via BTK | yes | 0 | |||||||
| clofarabine | RRM2 | SSL via RRM2 | yes | 0 | |||||||
| gallium citrate | RRM2 | SSL via RRM2 | yes | 0 | |||||||
| gallium citrate ga 67 | RRM2 | SSL via RRM2 | yes | 0 | |||||||
| gallium nitrate | RRM2 | SSL via RRM2 | yes | 0 | |||||||
| gallium oxodotreotide | RRM2 | SSL via RRM2 | yes | 0 | |||||||
| gallium oxodotreotide ga-68 | RRM2 | SSL via RRM2 | yes | 0 | |||||||
| gemcitabine | RRM2 | SSL via RRM2 | yes | 0 | |||||||
| gemcitabine hydrochloride | RRM2 | SSL via RRM2 | yes | 0 | |||||||
| glasdegib | SMO | SSL via SMO | yes | 0 | |||||||
| glasdegib maleate | SMO | SSL via SMO | yes | 0 | |||||||
| hydroxyurea | RRM2 | SSL via RRM2 | yes | 0 | |||||||
| lanreotide | SSTR5 | SSL via SSTR5 | yes | 0 | |||||||
| lanreotide acetate | SSTR5 | SSL via SSTR5 | yes | 0 | |||||||
| lemborexant | HCRTR1 | SSL via HCRTR1 | yes | 0 | |||||||
| octreotide | SSTR5 | SSL via SSTR5 | yes | 0 | |||||||
| octreotide acetate | SSTR5 | SSL via SSTR5 | yes | 0 | |||||||
| pasireotide | SSTR5 | SSL via SSTR5 | yes | 0 | |||||||
| pasireotide diaspartate | SSTR5 | SSL via SSTR5 | yes | 0 | |||||||
| pasireotide pamoate | SSTR5 | SSL via SSTR5 | yes | 0 | |||||||
| sonidegib | SMO | SSL via SMO | yes | 0 | |||||||
| sonidegib phosphate | SMO | SSL via SMO | yes | 0 | |||||||
| suvorexant | HCRTR1 | SSL via HCRTR1 | yes | 0 | |||||||
| vismodegib | SMO | SSL via SMO | yes | 0 | |||||||
| zanubrutinib | BTK | SSL via BTK | yes | 0 |